Evidence mapPaperPMID 39204362Full record

ReviewPharmaceutics2024

Advances in Light-Responsive Smart Multifunctional Nanofibers: Implications for Targeted Drug Delivery and Cancer Therapy.

Ahmed M Agiba, Nihal Elsayyad, Hala N ElShagea, Mahmoud A Metwalli, Amin Orash Mahmoudsalehi, Saeed Beigi-Boroujeni, Omar Lozano, Alan Aguirre-Soto, Jose Luis Arreola-Ramirez, Patricia Segura-Medina and 1 more

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmed M AgibaSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico.ORCID 0000-0003-3635-9093
Nihal ElsayyadDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October for Modern Sciences and Arts University, Cairo 12451, Egypt.ORCID 0000-0003-4601-0020
Hala N ElShageaDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ahram Canadian University, Cairo 12451, Egypt.ORCID 0000-0002-0873-8662
Mahmoud A MetwalliEl Demerdash Hospital, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.ORCID 0009-0006-9879-2385
Amin Orash MahmoudsalehiSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico.ORCID 0000-0002-8572-0992
Saeed Beigi-BoroujeniSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico.ORCID 0000-0002-0045-979X
Omar LozanoSchool of Medicine and Health Sciences, Tecnológico de Monterrey, Monterrey 64849, Mexico.
Alan Aguirre-SotoSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico.ORCID 0000-0003-0455-5401
Jose Luis Arreola-RamirezDepartment of Bronchial Hyperresponsiveness, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Mexico City 14080, Mexico.ORCID 0000-0003-4868-9241
Patricia Segura-MedinaDepartment of Bronchial Hyperresponsiveness, National Institute of Respiratory Diseases "Ismael Cosío Villegas", Mexico City 14080, Mexico.ORCID 0000-0002-5562-1715
Raghda Rabe HamedDepartment of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Cairo 12566, Egypt.ORCID 0000-0002-2389-2588

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decade, scientists have shifted their focus to the development of smart carriers for the delivery of chemotherapeutics in order to overcome the problems associated with traditional chemotherapy, such as poor aqueous solubility and bioavailability, low selectivity and targeting specificity, off-target drug side effects, and damage to surrounding healthy tissues. Nanofiber-based drug delivery systems have recently emerged as a promising drug delivery system in cancer therapy owing to their unique structural and functional properties, including tunable interconnected porosity, a high surface-to-volume ratio associated with high entrapment efficiency and drug loading capacity, and high mass transport properties, which allow for controlled and targeted drug delivery. In addition, they are biocompatible, biodegradable, and capable of surface functionalization, allowing for target-specific delivery and drug release. One of the most common fiber production methods is electrospinning, even though the relatively two-dimensional (2D) tightly packed fiber structures and low production rates have limited its performance. Forcespinning is an alternative spinning technology that generates high-throughput, continuous polymeric nanofibers with 3D structures. Unlike electrospinning, forcespinning generates fibers by centrifugal forces rather than electrostatic forces, resulting in significantly higher fiber production. The functionalization of nanocarriers on nanofibers can result in smart nanofibers with anticancer capabilities that can be activated by external stimuli, such as light. This review addresses current trends and potential applications of light-responsive and dual-stimuli-responsive electro- and forcespun smart nanofibers in cancer therapy, with a particular emphasis on functionalizing nanofiber surfaces and developing nano-in-nanofiber emerging delivery systems for dual-controlled drug release and high-precision tumor targeting. In addition, the progress and prospective diagnostic and therapeutic applications of light-responsive and dual-stimuli-responsive smart nanofibers are discussed in the context of combination cancer therapy.

Indexed as

cancer therapydual-stimuli-responsive smart nanofiberselectrospinningforcespinninglight-responsive smart nanofibersnanofiber-based drug delivery systemsnano-in-nanofiber emerging delivery systemssurface functionalization

Identifiers

PMID39204362
PMCPMC11359459

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.